Genes important for DNA processing appear to be good targets for reducing pulmonary hypertension.

Published Date: 15 Mar 2023

Vascular smooth muscle cells, which always provide strength and flexibility to the vascular wall, proliferate and are damaged in pulmonary hypertension.

Read Full News

Latest News

Tips for Clinicians Diagnosing Patients with Diverse Skin Types Mona Shahriari, MD, FAAD, Jennifer Soung, MD

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

Where Does Ameluz PDT Fit Alongside Mohs Surgery? Neal Bhatia, MD

Where does Ameluz PDT fit next to Mohs surgery for skin cancer? Neal Bhatia, MD, on candidacy, adoption, and open questions.

7 Dermatology Headlines You Missed in September 2026

7 Dermatology Headlines You Missed in September 2026

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

Where does Ameluz PDT fit next to Mohs surgery for skin cancer? Neal Bhatia, MD, on candidacy, adoption, and open questions.

7 Dermatology Headlines You Missed in September 2026

News All Time

CUPID A and C: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU Tim Smith

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

The Present and Future of Precision Medicine in Dermatology, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, discusses why precision medicine has advanced further in psoriasis than atopic dermatitis, and what oncology can teach dermatology.

FDA Approves First Oral Treatment of Dermatomyositis in Adult Patients Tim Smith

The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adults.

Resilience in Medicine, HS Treatments, and the Oral JAK Pipeline Today Lisa A. Swanson, MD

Lisa Swanson, MD, on embracing failure in medicine and the oral JAK inhibitors advancing for hidradenitis suppurativa and alopecia areata.

How Failure Is the Stepping Stone to Success, With Lisa Swanson, MD Lisa A. Swanson, MD

Lisa Swanson, MD, on treating professional failure as a source of direction and resilience in her LEADderm 2026 talk.

Competition, Burnout, and the Cost of Always Saying 'Yes' as a Clinician Adam Friedman, MD, FAAD

Adam Friedman, MD, traces dermatology's yes-first culture to residency competition, previewing an unrehearsed LEADderm 2026 negotiation exercise.

Tips on Saying 'No' as a Dermatology Leader, With Adam Friedman, MD Adam Friedman, MD, FAAD

Adam Friedman, MD, discusses saying no strategically as a career skill in a LEADderm 2026 table talk on managing opportunities.

6 Dermatology Headlines You Missed in August 2026 Tim Smith

A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.

Skin Angels and the Atopic Dermatitis Pipeline, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, on Skin Angels, a dermatology-focused angel-investing group that has evaluated over 300 companies and funded more than 30.

Reaching Patients Online and Avoiding Burnout, With Steven Daveluy, MD Steven Daveluy, MD, FAAD

Steven Daveluy, MD, speaks on why dermatologists belong on social media, avoiding burnout in practice, and what excites him in HS treatment.

Why Dermatologists Should Have a Seat at the Investment Table, With Manju Dawkins, MD Manju Dawkins, MD

A dermatologist-turned-entrepreneur on why clinicians belong in dermatology's investment decisions, and what excites her about the field's direction.

How Skin Angels Backs Dermatology's Next Innovators, With Ross Levy, MD Ross M. Levy, MD

Ross Levy, MD, on how Skin Angels invests in dermatology innovation and where he sees the field heading over the next 5 - 10 years.

Dermatology's Path From Idea to Innovation, With Ross Levy, MD Ross M. Levy, MD

Ross Levy, MD, explains why the LEADderm Skin Angels panel matters and what dermatology innovation looks like in daily practice.

Recommended News For You

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Race, Geography Linked to Gaps in Prostate Cancer Care

Novel probes to label macrophages associated with cancer progression using a selective dye

Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

Time to Rethink Maintenance Pemetrexed in NSCLC?

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

Recommended Articles For You

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment 

Circulating Tumor DNA Dynamics for Therapy Matching: A Comprehensive Clinical Review 

Quality of Life Through Personalized Survivorship Navigation After Multimodal Cancer Therapy 

Screening for Early Changes in Blood-Cell Production Capacity in Older Adults 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TULSA Is Effective in Long-Term Prostate Cancer Control.

2.

AVD Chemo Regimen Shows Promise in Older Patients With HL

3.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

4.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

5.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

1.

Programmable Cell Therapies for Selective Removal of Dysfunctional Hematopoietic Cell Populations

2.

Contemporary Insights in Oncology in the Digital Era

3.

Strategic Concepts in Hematology for Modern Medicine

4.

Ferroptosis-Modulating Therapeutics in Precision Oncology

5.

Exploring the Potential of Bendamustine in Cancer Treatment

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

2.

Blood Clotting Disorders Explained

3.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

4.

Chemotherapy: What to Expect

5.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot